WO2019061491A1 - Eye-care peptide, its composition and method of using the same - Google Patents
Eye-care peptide, its composition and method of using the same Download PDFInfo
- Publication number
- WO2019061491A1 WO2019061491A1 PCT/CN2017/104991 CN2017104991W WO2019061491A1 WO 2019061491 A1 WO2019061491 A1 WO 2019061491A1 CN 2017104991 W CN2017104991 W CN 2017104991W WO 2019061491 A1 WO2019061491 A1 WO 2019061491A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- eye
- composition
- migration
- subject
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates generally to a peptide effective for keeping eye health, its composition and method of using the same.
- a peptide having the amino acid sequence of ArgAsnProLeuGluGluThr (SEQ ID NO: 1) has an effect in enhancing the migration of corneal epithelial cells, which is beneficial to eye care or eye health.
- the present invention provides in one aspect a synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 1, which is also named as “Peptide No. 12” herein.
- the peptide provides an effect in enhancing the migration of corneal epithelial cells.
- the present invention provides a composition or a pharmaceutical composition benefic to eye care or eye health, comprising an effective amount of the peptide of SEQ ID NO: 1, and a pharmaceutically acceptable carrier.
- the composition of the invention is formulated in a systemic or topical form.
- the composition is formulated in a topical form, such as eye drop.
- the present invention provides an eye-care method for preventing eye damage, which comprises administering to a subject in need thereof the peptide having the amino acid sequence of SEQ ID NO: 1 in an amount effective to enhance the migration of corneal epithelial cells in the subject.
- the peptide is topically administered to the subject.
- Fig. 1A and Fig. 1B show that Peptide NO. 12 enhanced migration of HCEC corneal epithelial cells for 24 hours; wherein Fig. 1A provides some representative images of cell migration for 24 hours analyzed by Transwell migration assay in HCEC cells treated with different concentrations of Peptide NO. 12 for 24 hours (Scale bar, 1 mm) ; and Fig. 1B provides the results of the statistic analysis of migration for 24 hours (*: P ⁇ 0.05) .
- Fig. 2A and Fig. 2B show that Peptide NO. 12 enhanced migration of HCEC corneal epithelial cells for 48 hours; wherein Fig. 2A provides some representative images of cell migration in which the cells were treated with different concentrations of Peptide NO. 12 and analyzed by Transwell migration assay in HCEC cells for 48 hours (Scale bar, 1 mm) ; and Fig. 2B provides the results of the statistic analysis of migration for 48 hours (**: P ⁇ 0.01) .
- Fig. 3 shows that Peptide NO. 12 did not significantly affect viability of HCEC cells for 24 hours; wherein the HCEC cells were treated with different concentrations of Peptide NO. 12 for 24 hours and then analyzed by MTT assays.
- Fig. 4 shows that Peptide NO. 12 did not significantly affect viability of HCEC cells for 48 hours; wherein the HCEC cells were treated with different concentrations of Peptide NO. 12 for 48 hours and then analyzed by MTT assays.
- peptide is used herein in its conventional sense, i.e., a polymer in which the monomers are amino acids and are joined together through amide bonds, alternatively referred to as a polypeptide.
- amino acids are ⁇ -amino acids
- either the L-optical isomer or the D-optical isomer may be used.
- unnatural amino acids for example, ⁇ -alanine, phenylglycine and homoarginine are also meant to be included. Standard abbreviations for amino acids are used.
- the term “subject” refers to a vertebrate or vertebrates, preferably mammals, including, for example, humans, laboratory animals such as rats and mice, and farm animals, such as horses and cows; particularly humans.
- a human serving as a subject is specifically referred to as a “human subject. ”
- carrier or “cosmetically or pharmaceutically acceptable carrier” refers to any material commonly used on the formulations of cosmetic or pharmaceutical compositions used to enhance stability, sterility and deliverability.
- the delivery system is in an acceptable carrier, preferably an aqueous carrier.
- aqueous carriers may be used, e.g., water, buffered water, 0.8%saline, 0.3%glycine, hyaluronic acid and the like.
- compositions may contain physiologically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
- physiologically acceptable auxiliary substances such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
- systemic refers to a route of administration of medication or other substance into the circulatory system so that the entire body of a subject to be administered is affected.
- the administration may take place via enteral administration (through which the absorption of the medication or other substance through gastrointestinal tracts) or parenteral administration such as injection, infusion or implantation.
- Topical or “topically” is used herein its conventional sense as referring to a spot which can be in or on any part of the body, including but not limited to an eye or eyes, or any other part of the body.
- Topical administration or application means the direct contact of the peptide with tissue, such as a cornea.
- the term “effective amount” as used herein refers to a sufficient amount of the peptide according to the invention to provide desired therapeutic or healthcare effects, or the induction of a particular type of response.
- the effective amount required varies from subject to subject, depending on the disease state, physical conditions, age, sex, species and weight of the subject, etc. However, an appropriate effective amount can be determined by one of ordinary skill in the art using only routine experimentation.
- the peptide according to the invention may be administered systemically or topically.
- pharmaceutically acceptable carrier encompasses any of the standard pharmaceutical carriers.
- Such carriers may include, but are not limited to: saline, buffered saline, dextrose, water, glycerol, ethanol, propylene glycol, cremophor, nanoparticles, liposome, polymer, and combinations thereof.
- a pharmaceutical composition of the present invention may be supplemented with one or more excipients that are normally employed in common standard formulations, such as surfactants, solubilizers, stabilizers, emulsifiers, thickeners, and preservatives. Such excipients are well known to those skilled in the art.
- the peptide having the amino acid sequence of SEQ ID NO: 1 which may be artificially synthesized by a standard method or in any manner commonly used or known to one of ordinary skill. It was confirmed to have an effect in enhancing the migration of corneal epithelial cells, but not the growth of the cells. Therefore, the invention also provides a an eye-care method for preventing eye damage, which comprises administering to a subject in need thereof the peptide having the amino acid sequence of SEQ ID NO: 1 (also named as “Peptide No. 12) in an amount effective to enhance the migration of corneal epithelial cells in the subject.
- the present invention provides the use of the peptide of the invention for manufacturing a pharmaceutical or healthcare composition benefic to eye care or eye health.
- the invention provides a composition or a pharmaceutical composition benefic to eye care or eye health, comprising an effective amount of the peptide of SEQ ID NO: 1, and a pharmaceutically acceptable carrier.
- the pharmaceutical composition of the present invention may be constituted with one or more pharmaceutically acceptable carriers into any form suitable for the mode of administration selected, including systemic and topical administrations via enteral or parenteral administration such as injection, infusion or implantation, oral, transdermal or topical administration.
- the composition may be formulated with a pharmaceutically or cosmetically acceptable carrier as a topical formulation in a solution, ointment, gel, serum, cream, lotion, powder, emulsion or any form for administration.
- the formulation may be administered in a form of eye drop.
- the peptide consisting of the sequence of ArgAsnProLeuGluGluThr (SEQ ID NO: 1) was synthesized by MDBio, Inc. (Taipei, Taiwan) and the purity and composition of peptide was confirmed by high performance liquid chromatography (HPLC) and mass spectrometry. Peptide stock was stored at -20°C after dissolving 10 mg of lyophilized peptide powder in 250 ⁇ l of double deionized water (dd H 2 O) .
- Human corneal epithelial cell line, HCEC was cultured in complete KSF containing keratinocyte-serum free medium, 5 ng/ml human recombinant EGF, 0.05 mg/ml bovine pituitary extract, 0.005 mg/ml insulin and 500 ng/ml hydrocortisone under 5%CO 2 at 37 °C.
- HCEC corneal epithelial cells were treated with 0, 2, 5, 10 and 25 ⁇ g/ml of Peptide NO. 12, for 24 and 48 hours respectively, and then was analyzed by transwell migration assay.
- Peptide NO. 12 enhanced the migration of HCEC corneal epithelial cells.
- Peptide NO. 12 in either of the concentrations of 5, 10, 25 and 50 ⁇ g/ml did not significantly affect viability of HCEC cells for 24 and 48 hours, respectively.
- the peptide of SEQ ID NO: 1 provide an unexpected efficacy in the enhancement of the migration of migration of corneal epithelial cells, instead of the cell viability f corneal epithelial cells.
Abstract
Disclosed is a synthetic peptide consisting of an amino acid sequence of ArgAsnProLeuGluGluThr (SEQ ID NO: 1). Also provided are a pharmaceutical composition benific to eye care or eye health comprising the peptide, and a method for wound healing using the peptide.
Description
The present invention relates generally to a peptide effective for keeping eye health, its composition and method of using the same.
It cannot do without eyes to operate computer, watch television, read books and newspaper, drive vehicle and play chess. Recently, most people spend much time in watching videos through non-mobile or mobile devices, such televisions, computers, desktops, laptops, tablets, phones etc., to cause visual impairment or a series of symptom such as eye dryness, discomfort, irritation, burning, redness, excess tearing, blurred vision, eye fatigue, soreness, strain, fear light, myopia, myopic astigmatism.
To prevent from any damage in eyes, there are many methods as developed in different ways. For example, it is easy to palliate eyestrain in our life by sleeping, dozing, closing eyes, sports, music, looking far, massaging eyes, wearing sunglasses, taking vitamins, taking eye drops, and so on.There are other methods to reduce irritation of eyes.
In conformity with such need in eye health, medicament, such as vitamins or herbal medicines or combinations thereof, have been proposed. But up to now, the medicaments beneficial to eye health are uncertain.
It is still desired to find or develop a non-toxic, non-antigenic, inexpensive eye-care agent for eye health.
BRIEF SUMMARY OF THE INVENTION
It is unexpectedly found in the present invention that a peptide having the amino acid sequence of ArgAsnProLeuGluGluThr (SEQ ID NO: 1) has an effect in enhancing the migration of corneal epithelial cells, which is benefic to eye care or eye health.
Accordingly, the present invention provides in one aspect a synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 1, which is also named as “Peptide No. 12” herein. The peptide provides an effect in enhancing the migration of corneal epithelial cells.
In another aspect, the present invention provides a composition or a pharmaceutical composition benefic to eye care or eye health, comprising an effective amount of the peptide of SEQ ID NO: 1, and a pharmaceutically acceptable carrier.
In one embodiment of the invention, the composition of the invention is formulated in a systemic or topical form. In one particular example, the composition is formulated in a topical form, such as eye drop.
In one further aspect, the present invention provides an eye-care method for preventing eye damage, which comprises administering to a subject in need thereof the peptide having the amino acid sequence of SEQ ID NO: 1 in an amount effective to enhance the migration of corneal epithelial cells in the subject.
In one embodiment of the method according to the invention, the peptide is topically administered to the subject.
It is to be understood that both the foregoing general description and the following description are exemplary and explanatory only and are not restrictive of the invention.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred.
In the drawings:
Fig. 1A and Fig. 1B show that Peptide NO. 12 enhanced migration of HCEC corneal epithelial cells for 24 hours； wherein Fig. 1A provides some representative images of cell migration for 24 hours analyzed by Transwell migration assay in HCEC cells treated with different concentrations of Peptide NO. 12 for 24 hours (Scale bar, 1 mm) ； and Fig. 1B provides the results of the statistic analysis of migration for 24 hours (*: P < 0.05) .
Fig. 2A and Fig. 2B show that Peptide NO. 12 enhanced migration of HCEC corneal epithelial cells for 48 hours； wherein Fig. 2A provides some representative images of cell migration in which the cells were treated with different concentrations of Peptide NO. 12 and analyzed by Transwell migration assay in HCEC cells for 48 hours (Scale bar, 1 mm) ； and Fig. 2B provides the results of the statistic analysis of migration for 48 hours (**: P < 0.01) .
Fig. 3 shows that Peptide NO. 12 did not significantly affect viability of HCEC cells for 24 hours； wherein the HCEC cells were treated with different concentrations of Peptide NO. 12 for 24 hours and then analyzed by MTT assays.
Fig. 4 shows that Peptide NO. 12 did not significantly affect viability of HCEC cells for 48 hours； wherein the HCEC cells were treated with different concentrations of Peptide NO. 12 for 48 hours and then analyzed by MTT assays.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention belongs.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention belongs.
The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one, ” but it is also consistent with the meaning of “one or more, ” “at least one, ” and “one or more than one. ”
The term “peptide” is used herein in its conventional sense, i.e., a polymer in which the monomers are amino acids and are joined together through amide bonds, alternatively referred to as a polypeptide. When the amino acids are α-amino acids, either the L-optical isomer or the D-optical isomer may be used. Additionally, unnatural amino acids, for example, β-alanine, phenylglycine and homoarginine are also meant to be included. Standard abbreviations for amino acids are used.
As used herein, the term “subject” refers to a vertebrate or vertebrates, preferably mammals, including, for example, humans, laboratory animals such as rats and mice, and farm animals, such as horses and cows； particularly humans. Hereinafter, a human serving as a subject is specifically referred to as a “human subject. ”
As used herein, the term “carrier” or "cosmetically or pharmaceutically acceptable carrier" refers to any material commonly used on the formulations of cosmetic or pharmaceutical compositions used to enhance stability, sterility and deliverability. When the peptide delivery system is formulated as a solution or suspension, the delivery system is in an acceptable carrier,
preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8％saline, 0.3％glycine, hyaluronic acid and the like. The compositions may contain physiologically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
The term "systemic" or "systemically" as used herein refers to a route of administration of medication or other substance into the circulatory system so that the entire body of a subject to be administered is affected. The administration may take place via enteral administration (through which the absorption of the medication or other substance through gastrointestinal tracts) or parenteral administration such as injection, infusion or implantation.
The term “topical” or “topically” is used herein its conventional sense as referring to a spot which can be in or on any part of the body, including but not limited to an eye or eyes, or any other part of the body. Topical administration or application means the direct contact of the peptide with tissue, such as a cornea.
The term “effective amount” as used herein refers to a sufficient amount of the peptide according to the invention to provide desired therapeutic or healthcare effects, or the induction of a particular type of response. The effective amount required varies from subject to subject, depending on the disease state, physical conditions, age, sex, species and weight of the subject, etc. However, an appropriate effective amount can be determined by one of ordinary skill in the art using only routine experimentation. For example, the peptide according to the invention may be administered systemically or topically.
The term “pharmaceutically acceptable carrier” as used herein encompasses any of the standard pharmaceutical carriers. Such carriers may include, but are not limited to: saline, buffered saline, dextrose, water, glycerol, ethanol, propylene glycol, cremophor, nanoparticles, liposome, polymer, and combinations thereof. In addition to standard carriers, a pharmaceutical composition of the present invention may be supplemented with one or more excipients that are normally employed in common standard formulations, such as surfactants, solubilizers, stabilizers, emulsifiers, thickeners, and preservatives. Such excipients are well known to those skilled in the art.
As shown in the examples, the peptide having the amino acid sequence of SEQ ID NO: 1, which may be artificially synthesized by a standard method or in any manner commonly used or known to one of ordinary skill. It was confirmed to have an effect in enhancing the migration of corneal epithelial cells, but not the growth of the cells. Therefore, the invention also provides a an eye-care method for preventing eye damage, which comprises administering to a subject in need thereof the peptide having the amino acid sequence of SEQ ID NO: 1 (also named as “Peptide No. 12) in an amount effective to enhance the migration of corneal epithelial cells in the subject.
On the other hand, the present invention provides the use of the peptide of the invention for manufacturing a pharmaceutical or healthcare composition benefic to eye care or eye health.
In addition, the invention provides a composition or a pharmaceutical composition benefic to eye care or eye health, comprising an effective amount of the peptide of SEQ ID NO: 1, and a pharmaceutically acceptable carrier.
The pharmaceutical composition of the present invention may be constituted with one or more pharmaceutically acceptable carriers into any form suitable for the mode of administration selected, including systemic and topical administrations via enteral or parenteral administration such as injection, infusion or implantation, oral, transdermal or topical administration. In certain embodiments of the invention, the composition may be formulated with a pharmaceutically or cosmetically acceptable carrier as a topical formulation in a solution, ointment, gel, serum, cream, lotion, powder, emulsion or any form for administration. In one particular example, the formulation may be administered in a form of eye drop.
The present invention is further illustrated by the following examples, which are provided for the purpose of demonstration rather than limitation.
Examples
Example 1: Preparation of Peptide No. 12
The peptide consisting of the sequence of ArgAsnProLeuGluGluThr (SEQ ID NO: 1) was synthesized by MDBio, Inc. (Taipei, Taiwan) and the purity and composition of peptide was confirmed by high performance liquid chromatography (HPLC) and mass spectrometry. Peptide stock was stored at -20℃ after dissolving 10 mg of lyophilized peptide powder in 250 μl of double deionized water (dd H2O) .
Example 2: Efficacy Experiment
Materials and Method
Cell culture
Human corneal epithelial cell line, HCEC, was cultured in complete KSF containing keratinocyte-serum free medium, 5 ng/ml human recombinant EGF, 0.05 mg/ml bovine pituitary extract, 0.005 mg/ml insulin and 500 ng/ml hydrocortisone under 5％CO2 at 37 ℃.
Transwell migration assay
Cells (3.5 × 104) in 0.25 ml keratinocyte-serum free medium were seeded into the upper chamber with an 8-μm pore size membrane (Corning, USA) and 0.5 ml 10％complete KSF with or without peptide NO. 12 were loaded to the lower chamber in 24-well culture plate. After 24-hour or 48-hour incubation, cells were fixed and stained with 0.5％ (w/v) crystal violet (Sigma) containing 20％ (v/v) methanol. The migrated cells from 5 random fields were counted under a phase-contrast microscope. Results obtained were analyzed by student's t-test and graphed as mean ± SD.
MTT assay
Cells (2 × 104) in 1ml complete KSF were seeded in 12-well plates with or without Peptide NO. 12. Seventy microliters of 5 mg/ml 3- (4, 5-dimethyl-2-thiazolyl) -2, 5-diphenyl-2H-tetrazolium bromide solution (MTT； Sigma) was added to each well for the indicated times and incubated at 37℃ for 3 hours, after which 700 μl 10％SDS in 0.01 N HCl was added to dissolve the MTT formazan crystals. The resultant optical density was measured spectrophotometrically at dual wavelengths, 550 and 630 nm.
Results
The HCEC corneal epithelial cells were treated with 0, 2, 5, 10 and 25 μg/ml of Peptide NO. 12, for 24 and 48 hours respectively, and then was analyzed by transwell migration assay. As shown in Figs. 1A, 1B, 2A and 2B, Peptide NO. 12 enhanced the migration of HCEC corneal epithelial cells. However, as shown in Fig. 3 and Fig. 4, Peptide NO. 12 in either of the concentrations of 5, 10, 25 and 50 μg/ml, did not significantly affect viability of HCEC cells for 24 and 48 hours, respectively.
Given the above, it is concluded that the peptide of SEQ ID NO: 1 provide an unexpected efficacy in the enhancement of the migration of migration of corneal epithelial cells, instead of the cell viability f corneal epithelial cells.
It will be appreciated by those skilled in the art that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is
understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the appended claims.
Claims (10)
- A synthetic peptide consisting of the amino acid sequence of ArgAsnProLeuGluGluThr (SEQ ID NO: 1) .
- The peptide of claim 1, which has an effect in enhancing the migration of corneal epithelial cells.
- A composition or a pharmaceutical composition benefic to eye care or eye health, comprising the peptide of claim 1 in an amount effective to enhance the migration of fibroblast cells, and a pharmaceutically acceptable carrier.
- The composition of claim 3, which is formulated in a systemic or topical form.
- The composition of claim 3, which is formulated in a topical form
- The composition of claim 4, wherein the topical formulation is in a form of eye drop.
- An eye-care method for preventing eye damage, which comprises administering to a subject in need thereof the peptide of claim 1 in an amount effective to enhance the migration of corneal epithelial cells in the subject.
- The method of claim 8, wherein the peptide of claim 1 is systemically or topically administered to the subject.
- The method of claim 8, wherein the peptide of claim 1 is topically administered to the subject.
- The method of claim 8, wherein the peptide of claim 1 is formulated in a form of eye drop.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/104991 WO2019061491A1 (en) | 2017-09-30 | 2017-09-30 | Eye-care peptide, its composition and method of using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/104991 WO2019061491A1 (en) | 2017-09-30 | 2017-09-30 | Eye-care peptide, its composition and method of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019061491A1 true WO2019061491A1 (en) | 2019-04-04 |
Family
ID=65903829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2017/104991 WO2019061491A1 (en) | 2017-09-30 | 2017-09-30 | Eye-care peptide, its composition and method of using the same |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2019061491A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109912685A (en) * | 2017-12-13 | 2019-06-21 | 三凡生技研发股份有限公司 | Eye protection wins peptide and combinations thereof and the purposes using the victory peptide |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0914827A1 (en) * | 1996-06-26 | 1999-05-12 | Santen Pharmaceutical Co., Ltd. | Ophthalmic drug compositions |
| WO2013142229A1 (en) * | 2012-03-19 | 2013-09-26 | President And Fellows Of Harvard College | Designing novel peptides for inducing fibronectin matrix assembly |
| US8614103B2 (en) * | 2006-10-27 | 2013-12-24 | Lpath, Inc. | Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions |
| WO2016179007A1 (en) * | 2015-05-01 | 2016-11-10 | Allysta Pharmaceuticals, Inc. | Adiponectin peptidomimetics for treating ocular disorders |
-
2017
- 2017-09-30 WO PCT/CN2017/104991 patent/WO2019061491A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0914827A1 (en) * | 1996-06-26 | 1999-05-12 | Santen Pharmaceutical Co., Ltd. | Ophthalmic drug compositions |
| US8614103B2 (en) * | 2006-10-27 | 2013-12-24 | Lpath, Inc. | Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions |
| WO2013142229A1 (en) * | 2012-03-19 | 2013-09-26 | President And Fellows Of Harvard College | Designing novel peptides for inducing fibronectin matrix assembly |
| WO2016179007A1 (en) * | 2015-05-01 | 2016-11-10 | Allysta Pharmaceuticals, Inc. | Adiponectin peptidomimetics for treating ocular disorders |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109912685A (en) * | 2017-12-13 | 2019-06-21 | 三凡生技研发股份有限公司 | Eye protection wins peptide and combinations thereof and the purposes using the victory peptide |
| CN109912685B (en) * | 2017-12-13 | 2022-05-06 | 三凡生技研发股份有限公司 | Eye protection peptide, composition thereof and application of eye protection peptide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220306704A1 (en) | Neurotoxins for use in inhibiting cgrp | |
| EP2234644B1 (en) | Insulin formulations for insulin release as a function of tissue glucose levels | |
| KR20190053214A (en) | Stabilized non-protein clostridial toxin composition | |
| US20120003296A1 (en) | New methods of treating dry eye syndrome | |
| JP2013166792A (en) | Botulinum toxin for treatment of priapism | |
| US11779531B2 (en) | Anti-inflammatory peptides, and uses thereof | |
| IL218504A (en) | Lkktet and/or lkktnt peptides for treatment of dry eye syndrome | |
| US20160361388A1 (en) | Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca | |
| CN107952064B (en) | Pharmaceutical preparation containing polyethylene glycol lozenges and preparation method thereof | |
| KR20110020819A (en) | Pharmaceutical composition for treatment of dry eye and/or corneal/conjunctival disorders | |
| US10548941B2 (en) | Compositions and methods for treating diabetes, hypertension and hypercholesterolemia | |
| US10364270B2 (en) | Eye-care peptide, its composition and method of using the same | |
| CN104415326A (en) | Liraglutide-containing pharmaceutical preparation composition and preparation method thereof | |
| WO2019061491A1 (en) | Eye-care peptide, its composition and method of using the same | |
| CN103816115A (en) | Pharmaceutical composition containing fusion protein capable of inhibiting blood vessel hyperplasia and application thereof | |
| TW201350109A (en) | Methods and compositions for reducing ocular discomfort | |
| CN109912685B (en) | Eye protection peptide, composition thereof and application of eye protection peptide | |
| TWI674124B (en) | Eye-care peptide, its composition and method of using the same | |
| KR101514257B1 (en) | Pharmaceutical Composition and Quasi-Drug Cosmetic Using Same | |
| JPH07505156A (en) | Method for lowering intraocular pressure in mammalian eyes by administration of γ-aminobutyric acid (GABA) agonist | |
| US10232009B1 (en) | Peptide for promoting wound healing, its composition and method of using the same | |
| CN112535690A (en) | Oxygen supply and sterilization integrated ozone eye cleaning and nursing lotion | |
| JP7440126B2 (en) | Peptide-containing composition for treating neoplastic lesions | |
| WO2011040564A1 (en) | Ophthalmic agent comprising specific peptide compound as active ingredient | |
| TWI674276B (en) | Peptide for promoting wound healing, its composition and method of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17927783 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17927783 Country of ref document: EP Kind code of ref document: A1 |